

COPD Medications Coverage Summary

Drug		Non-Insured Health Benefits Coverage	Yukon Pharmacare/Chronic Disease Program
SABA	Bricanyl turbuhaler	Yes	Yes
	Ventolin MDI + generics	Yes	Yes
	Ventolin Diskus	NO	NO
SAMA	Atrovent MDI	Yes	Yes
SABA/SAMA	Combivent Respimat	Yes	Yes
ICS**note to use only with LABA for COPD	Alvesco MDI	Yes	Yes
	Asmanex twisthaler		
	Flovent MDI and diskus		
	Pulmicort turbuhaler		
	Qvar MDI		
LABA	Foradil Aerolizer	Limited Use	Exception
	Onbrez Breezhaler	Limited Use	Exception
	Oxeze turbuhaler	Not indicated for COPD	Exception **though not indicated for COPD
	Serevent Diskus	Limited Use	Exception
	Striverdi Respimat	NO	NO
LAMA	Incruse Ellipta	Limited Use	Exception
	Seebri Breezhaler	Limited Use	Exception
	Spiriva Respimat and Handihaler	Limited Use	Exception
	Tudorza Genuair	Limited Use	Exception
ICS/LABA	Advair MDI and diskus	Limited Use	Exception
	Breo Ellipta	Limited Use	Exception
	Symbicort Turbuhaler	Limited Use	Exception
	Zenhale MDI	Limited Use	Exception
LABA/LAMA	Anoro Ellipta	Limited Use	Exception
	Duaklir Genuair	Limited Use	Exception
	Inspiolto Respimat	Limited Use	Exception
	Ultibro Breezhaler	Limited Use	Exception
Methylxanthines	Theophylline	Yes	Yes
PDE-4 inhibitor	Daxas (roflumilast)	NO	NO

SABA: short acting beta agonist; SAMA: short acting muscarinic antagonist; ICS: inhaled corticosteroid; LABA: long acting beta agonist; LAMA: long acting muscarinic antagonist

Long Acting Beta Agonist (LABA):

Drug	NIHB	Yukon Pharmacare/Chronic Disease Program
Foradil Aerolizer (formoterol)	Not adequately controlled with either ipratropium, tiotropium or a short acting beta-agonist (SABA)	For moderate to severe COPD (MRC dyspnea scale 3-5 AND spirometric results: FEV1<60% and FEV1/FVC<0.7)
Onbrez Breezhaler (Indacaterol)	Did not respond to trial of ipratropium OR did not have trial of ipratropium, but who have moderate-severe COPD as defined by spirometry	For moderate to severe COPD (MRC dyspnea scale 3-5 AND spirometric results: FEV1<60% and FEV1/FVC<0.7)
Oxeze turbuhaler (formoterol)	Not indicated for COPD	For moderate to severe COPD (MRC dyspnea scale 3-5 AND spirometric results: FEV1<60% and FEV1/FVC<0.7) ***though not indicated for COPD
Serevent Diskus (salmeterol)	Not adequately controlled with either ipratropium, tiotropium or a short acting beta-agonist (SABA)	For moderate to severe COPD (MRC dyspnea scale 3-5 AND spirometric results: FEV1<60% and FEV1/FVC<0.7)
Striverdi Respimat (olodaterol)	Not on formulary	Not on formulary

Long Acting Muscarinic Antagonist (LAMA):

Drug	NIHB	Yukon Pharmacare/Chronic Disease Program
Incruse Ellipta (umeclidinium)	Patients who did not respond to trial of ipratropium OR did not have trial of ipratropium, but who have moderate-severe COPD as defined by spirometry	Persistent symptoms after 2-3 months of SABA or SAMA at optimal dose. Provide post-bronchodilator spirometry to show moderate to severe obstruction (FEV1<65% and FEV1/FVC<0.7 and MRC dyspnea scale 3-5). If spirometry can not be obtained, other evidence regarding severity of condition must be provided
Seebri Breezhaler (glycopyrronium)	Patients who did not respond to trial of ipratropium OR did not have trial of ipratropium, but who have moderate-severe COPD as defined by spirometry	Persistent symptoms after 2-3 months of SABA or SAMA at optimal dose. Provide post-bronchodilator spirometry to show moderate to severe obstruction (FEV1<65% and FEV1/FVC<0.7 and MRC dyspnea scale 3-5). If spirometry can not be obtained, other evidence regarding severity of condition must be provided
Spiriva Handihaler (tiotropium)	Patients who did not respond to trial of ipratropium OR did not have trial of ipratropium, but who have moderate-severe COPD as defined by spirometry	Persistent symptoms after 2-3 months of SABA or SAMA at optimal dose. Provide post-bronchodilator spirometry to show moderate to severe obstruction (FEV1<65% and FEV1/FVC<0.7 and MRC dyspnea scale 3-5). If spirometry can not be obtained, other evidence regarding severity of condition must be provided
Spiriva Respimat (tiotropium)	Patients who did not respond to trial of ipratropium OR did not have trial of ipratropium, but who have moderate-severe COPD as defined by spirometry	Persistent symptoms after 2-3 months of SABA or SAMA at optimal dose. Provide post-bronchodilator spirometry to show moderate to severe obstruction (FEV1<65% and FEV1/FVC<0.7 and MRC dyspnea scale 3-5). If spirometry can not be obtained, other evidence regarding severity of condition must be provided
Tudorza Genuair (Aclidinium)	Patients who did not respond to trial of ipratropium OR did not have trial of ipratropium, but who have moderate-severe COPD as defined by spirometry	Patients with spirometry measures of FEV1<65% AND FEV1/FVC<0.7 AND inadequate response after 3 month trial of ipratropium at maximum dosage

LABA/LAMA (Long Acting Beta Agonist/Long Acting Muscarinic Antagonist):

Drug	NIHB	Yukon Pharmacare/Chronic Disease Program
Anoro Ellipta (umeclidinium/vilanterol)	Patients who have moderate-severe COPD, defined by spirometry AND inadequate response to a LAMA or LABA	For treatment of moderate to severe COPD (MRC dyspnea scale 3-5 and spirometry results of FEV1<60% and FEV1/FVC<0.7) AND inadequate response to a LAMA or LABA
Duaklir Genuair (Aclidinium/formoterol)	Patients who have moderate-severe COPD, defined by spirometry AND inadequate response to a LAMA or LABA	For treatment of moderate to severe COPD (MRC dyspnea scale 3-5 and spirometry results of FEV1<60% and FEV1/FVC<0.7) AND inadequate response to a LAMA or LABA
Inspiroto Respimat (tiotropium/olodaterol)	Patients who have moderate-severe COPD, defined by spirometry AND inadequate response to a LAMA or LABA	For treatment of moderate to severe COPD (MRC dyspnea scale 3-5 and spirometry results of FEV1<60% and FEV1/FVC<0.7) AND inadequate response to a LAMA or LABA
Ultibro Breezhaler (Indacaterol/glycopyrronium)	Patients who have moderate-severe COPD, defined by spirometry AND inadequate response to a LAMA or LABA	For treatment of moderate to severe COPD (MRC dyspnea scale 3-5 and spirometry results of FEV1<60% and FEV1/FVC<0.7) AND inadequate response to a LAMA or LABA

ICS/LABA (Inhaled Corticosteroid/Long Acting Beta Agonist):

Drug	NIHB	Yukon Pharmacare/Chronic Disease Program
Advair MDI or diskus (fluticasone/salmeterol)	Patients who have moderate-severe COPD, defined by spirometry OR inadequate response to a LAMA or LABA	For treatment of moderate to severe COPD (MRC dyspnea scale 3-5 and spirometry results of FEV1<60% and FEV1/FVC<0.7)
Breo Ellipta (fluticasone furoate/vilanterol)	Patients who have moderate-severe COPD, defined by spirometry OR inadequate response to a LAMA or LABA	For treatment of moderate to severe COPD (MRC dyspnea scale 3-5 and spirometry results of FEV1<60% and FEV1/FVC<0.7)
Symbicort Turbuhaler (budesonide/formoterol)	Patients who have moderate-severe COPD, defined by spirometry OR inadequate response to a LAMA or LABA	For treatment of moderate to severe COPD (MRC dyspnea scale 3-5 and spirometry results of FEV1<60% and FEV1/FVC<0.7)
Zenhale MDI (mometasone/formoterol)	Not indicated for COPD	Not indicated for COPD

Updated: Dec 12, 2017

NIHB Formulary: <https://www.canada.ca/content/dam/hc-sc/documents/services/publications/health-system-services/non-insured-health-benefits-drug-benefit-list/dbl-2017-eng.pdf>

Yukon Pharmacare/Chronic Disease Program Formulary: <http://www.hss.gov.yk.ca/drugformulary.php>